| __timestamp | BioCryst Pharmaceuticals, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 85181000 |
| Thursday, January 1, 2015 | 72758000 | 135253000 |
| Friday, January 1, 2016 | 61008000 | 162297000 |
| Sunday, January 1, 2017 | 66962000 | 198442000 |
| Monday, January 1, 2018 | 84888000 | 226616000 |
| Tuesday, January 1, 2019 | 107068000 | 299726000 |
| Wednesday, January 1, 2020 | 122964000 | 335375000 |
| Friday, January 1, 2021 | 208808000 | 505748000 |
| Saturday, January 1, 2022 | 253297000 | 590453000 |
| Sunday, January 1, 2023 | 216566000 | 849658000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Jazz Pharmaceuticals plc and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D expenditures. Jazz Pharmaceuticals has consistently outpaced BioCryst, with its R&D spending peaking at approximately 850% higher in 2023 compared to 2014. This robust investment underscores Jazz's commitment to expanding its drug pipeline and enhancing therapeutic offerings.
Conversely, BioCryst Pharmaceuticals has shown a steady increase, with a notable 400% rise in R&D expenses from 2014 to 2022, reflecting its strategic focus on niche markets and rare diseases. The year 2021 marked a significant leap for both companies, with Jazz's R&D expenses surging by 52% and BioCryst's by 70%, highlighting a pivotal year of innovation. These trends reveal the dynamic nature of pharmaceutical R&D and its critical role in driving future growth.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Alpine Immune Sciences, Inc.
R&D Insights: How Jazz Pharmaceuticals plc and Ultragenyx Pharmaceutical Inc. Allocate Funds
Research and Development Investment: Jazz Pharmaceuticals plc vs Pharming Group N.V.
Comparing Innovation Spending: Jazz Pharmaceuticals plc and MorphoSys AG
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Geron Corporation
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.